Last Updated: June 30, 2026

Claims for Patent: 10,508,182

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,508,182

Title:	Durable superhydrophobic surfaces
Abstract:	A superhydrophobic appliance is an elastomeric material with a surface having a multiplicity of re-entrant features. The elastomeric material can be a polydimethylsiloxane network. The superhydrophobic appliance can be formed by infusing a portion of a polydimethylsiloxane polymeric precursor partially into the pores of a porous membrane, curing to the polymeric network, and separating the membrane from the appliance to expose the superhydrophobic surface. The superhydrophobic surface can be subsequently modified to form a fluorinated surface that is oleophobic or superoleophobic in addition to being superhydrophobic.
Inventor(s):	Wolfgang M. Sigmund, Shu-Hau Hsu, Ravi Kumar VASUDEVAN
Assignee:	Early Stage Technologies LLC , University of Florida Research Foundation Inc
Application Number:	US15/327,508

Details for Patent 10,508,182

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009	⤷ Start Trial	2035-07-24
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009	⤷ Start Trial	2035-07-24
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	⤷ Start Trial	2035-07-24
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	November 13, 2015	⤷ Start Trial	2035-07-24
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	October 25, 2016	⤷ Start Trial	2035-07-24
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	March 13, 2017	⤷ Start Trial	2035-07-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,508,182

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
United States of America	2017158831	⤷ Start Trial
United States of America	2020190276	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2016060723	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.